Zentalis Pharmaceuticals Llc Stock Buy Hold or Sell Recommendation
| ZNTL Stock | USD 3.63 0.15 4.31% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Zentalis Pharmaceuticals Llc is 'Strong Sell'. The recommendation algorithm takes into account all of Zentalis Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site.
Check out Zentalis Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Zentalis and provide practical buy, sell, or hold advice based on investors' constraints. Zentalis Pharmaceuticals Llc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Zentalis |
Execute Zentalis Pharmaceuticals Buy or Sell Advice
The Zentalis recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Zentalis Pharmaceuticals Llc. Macroaxis does not own or have any residual interests in Zentalis Pharmaceuticals Llc or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Zentalis Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Zentalis Pharmaceuticals Trading Alerts and Improvement Suggestions
| Zentalis Pharmaceuticals had very high historical volatility over the last 90 days | |
| Net Loss for the year was (292.19 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Zentalis Pharmaceuticals Llc currently holds about 455.22 M in cash with (207.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Zentalis Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm |
Zentalis Pharmaceuticals Returns Distribution Density
The distribution of Zentalis Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Zentalis Pharmaceuticals' future price movements. The chart of the probability distribution of Zentalis Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Zentalis Pharmaceuticals Llc price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Zentalis Pharmaceuticals returns is essential to provide solid investment advice for Zentalis Pharmaceuticals.
| Mean Return | 0.43 | Value At Risk | -8.64 | Potential Upside | 11.41 | Standard Deviation | 5.87 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Zentalis Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Zentalis Stock Institutional Investors
| Shares | Mpm Oncology Impact Management Lp | 2024-09-30 | 1.5 M | Geode Capital Management, Llc | 2024-09-30 | 1.3 M | D. E. Shaw & Co Lp | 2024-09-30 | 1.1 M | Opaleye Management Inc | 2024-09-30 | 967 K | Tybourne Capital Management (hk) Ltd | 2024-09-30 | 961.5 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 923.9 K | Two Sigma Investments Llc | 2024-09-30 | 908.6 K | Two Sigma Advisers, Llc | 2024-06-30 | 796.9 K | Goldman Sachs Group Inc | 2024-06-30 | 619.3 K | Matrix Capital Management Company, Llc | 2024-06-30 | 14 M | Eventide Asset Management, Llc | 2024-09-30 | 8.5 M |
Zentalis Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (352K) | (284.8M) | 2.3M | (111.6M) | (14.3M) | (15.0M) | |
| Change In Cash | 42.3M | (11.2M) | 6.3M | (16.9M) | (15.0M) | (14.2M) | |
| Free Cash Flow | (39.5M) | (87.6M) | (160.2M) | (166.3M) | (208.4M) | (198.0M) | |
| Depreciation | 111K | 160K | 544K | 1.4M | 1.4M | 1.5M | |
| Other Non Cash Items | (7.8M) | 556K | (38.4M) | 12.6M | 23.1M | 24.3M | |
| Capital Expenditures | 352K | 758K | 6.1M | 2.5M | 583K | 553.9K | |
| Net Income | (46.4M) | (118.5M) | (166.1M) | (237.1M) | (292.2M) | (277.6M) | |
| End Period Cash Flow | 67.5M | 56.3M | 62.6M | 45.7M | 30.7M | 38.4M | |
| Change To Netincome | (98K) | 23.0M | 46.4M | 62.4M | 71.8M | 75.4M |
Zentalis Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Zentalis Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Zentalis Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Zentalis stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.11 | |
β | Beta against Dow Jones | 2.70 | |
σ | Overall volatility | 5.86 | |
Ir | Information ratio | 0.05 |
Zentalis Pharmaceuticals Volatility Alert
Zentalis Pharmaceuticals Llc exhibits above-average semi-deviation for your current time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Zentalis Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Zentalis Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Zentalis Pharmaceuticals Fundamentals Vs Peers
Comparing Zentalis Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Zentalis Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Zentalis Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Zentalis Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Zentalis Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Zentalis Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Zentalis Pharmaceuticals to competition |
| Fundamentals | Zentalis Pharmaceuticals | Peer Average |
| Return On Equity | -0.43 | -0.31 |
| Return On Asset | -0.25 | -0.14 |
| Operating Margin | (5.16) % | (5.51) % |
| Current Valuation | (102.79 M) | 16.62 B |
| Shares Outstanding | 71.27 M | 571.82 M |
| Shares Owned By Insiders | 3.83 % | 10.09 % |
| Shares Owned By Institutions | 98.05 % | 39.21 % |
| Number Of Shares Shorted | 4.97 M | 4.71 M |
| Price To Book | 0.70 X | 9.51 X |
| Price To Sales | 6.38 X | 11.42 X |
| EBITDA | (275.5 M) | 3.9 B |
| Net Income | (292.19 M) | 570.98 M |
| Cash And Equivalents | 455.22 M | 2.7 B |
| Cash Per Share | 7.99 X | 5.01 X |
| Total Debt | 43.15 M | 5.32 B |
| Debt To Equity | 0.1 % | 48.70 % |
| Current Ratio | 9.61 X | 2.16 X |
| Book Value Per Share | 4.98 X | 1.93 K |
| Cash Flow From Operations | (207.82 M) | 971.22 M |
| Short Ratio | 3.27 X | 4.00 X |
| Earnings Per Share | (2.61) X | 3.12 X |
| Target Price | 9.5 | |
| Number Of Employees | 124 | 18.84 K |
| Beta | 1.74 | -0.15 |
| Market Capitalization | 258.69 M | 19.03 B |
| Total Asset | 551.69 M | 29.47 B |
| Retained Earnings | (888.56 M) | 9.33 B |
| Working Capital | 427.35 M | 1.48 B |
| Net Asset | 551.69 M |
Note: Acquisition by Roth Iris of 297500 shares of Zentalis Pharmaceuticals at 18.87 subject to Rule 16b-3 [view details]
Zentalis Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Zentalis . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Zentalis Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Zentalis Pharmaceuticals Llc? Buying financial instruments such as Zentalis Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Zentalis Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Apparel Thematic Idea Now
Apparel
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Apparel theme has 49 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Apparel Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Zentalis Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.61) | Revenue Per Share 0.572 | Return On Assets (0.25) | Return On Equity (0.43) |
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.